NasdaqGS:RIGLBiotechs
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU
Earlier in May 2026, Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA‑approved oral PROTAC for certain advanced or metastatic ER+/HER2-, ESR1‑mutated breast cancers.
This deal makes VEPPANU Rigel’s fourth commercial product and the first approved PROTAC in its portfolio, potentially reshaping the company’s oncology focus and product mix.
We’ll now examine how adding VEPPANU as a globally licensed, FDA‑approved...